Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SLS
SELLAS LIFE SCIENCES GROUP, INC.
NASDAQ
$13.21
▼ DOWN 13.15% (-2.00)

KEY STATISTICS

Market Cap$2.46 B
52w High$15.88
52w Low$1.39
Dividend Yield—
Frequency—
P/E-62.90
Volume9.76M
Shares Out.186.03M

COMPANY

LEADERSHIP

Angelos Stergiou
CHIEF EXECUTIVE
Angelos Stergiou

COMPENSATION 2026

Salary$676,000
Stock Awards$477,107
Incentive Plan Pay$390,390
All Other Comp.$5
Total$1,877,810

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 12, 2008
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
13

PRICE TARGET

Target High$35.00
Target Low$35.00
Target Median$35.00
Target Consensus$35.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2019-11-08Reverse1:50
2018-01-02Reverse1:30
2016-11-14Reverse1:20

PRICE

$13.21 ▼ DOWN 13.15% (−$2.00)
OVERLAYS
$13.50$14.00$14.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.21

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com ↗

SELLAS Life Sciences develops novel cancer immunotherapies, including GPS and nelipepimut-S, with lead candidates in Phase III and Phase 2 trials, and collaborates with Merck to evaluate combination treatments for various cancers.

INDUSTRY

Biotechnology

A PRODUCT SELLAS LIFE SCIENCES GROUP, INC. IS KNOWN FOR

Galinpepimut-S (GPS)
Galinpepimut-S (GPS)

Galinpepimut-S (GPS) by SELLAS Life Sciences is a cancer immunotherapy targeting WT1 protein, in Phase 3 trials for AML, representing the company's most advanced effort to develop a novel cancer treatment.

COMPETITORS

COMPETITOR
GILD COMPARE
MRKR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
98
LISTED HERE
19
RANKED BY POSITION SIZE
XBI
1.17% · 9.2M
VTS.AX
0.00% · 5.9M
XSU.TO
0.08% · 4.9M
LABU
0.80% · 334.5K
DWAS
1.01% · 287.0K
SBIO
1.26% · 229.5K
XRS2.DE
0.09% · 169.0K
ETHO
0.90% · 133.0K
RSSL
0.09% · 90.1K
FHLC
0.04% · 85.9K
GSSC
0.11% · 78.0K
ULTI
5.06% · 72.6K
AFSM
0.47% · 40.8K
BBC
1.16% · 40.1K
RTWO.L
0.06% · 9.0K
URTY
0.03% · 7.7K
RFLR
0.08% · 5.5K
PWS
0.24% · 4.0K
RESM
0.09% · 361

INSTITUTIONAL OWNERSHIP

SHARES OWNED
32.12%
HOLDERS
232
TOP 12 OF 232 · RANKED BY POSITION SIZE
Blackrock, Inc.
15.1M sh · $222.44M
State Street Corp
13.0M sh · $191.83M
Vanguard Group Inc
8.5M sh · $31.92M
Anson Funds Management LP
6.0M sh · $9.71M
Geode Capital Management, LLC
4.9M sh · $72.11M
Marshall Wace, Llp
2.4M sh · $3.8M
Jones Financial Companies Lllp
2.3M sh · $28.55M
Susquehanna International Group, Llp
2.1M sh · $30.27M
Northern Trust Corp
1.6M sh · $23.91M
Millennium Management LLC
1.4M sh · $5.23M
Morgan Stanley
1.3M sh · $5.65M
Ubs Group AG
1.3M sh · $18.49M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Stergiou Angelos M.
Purchase · 1.1M shares
2026-06-16
★
OFFICER: CFO
Burns John Thomas
Purchase · 300.0K shares
2026-01-07
★
DIRECTOR
Kalin Katherine Bach
Purchase · 50.0K shares
2026-01-07
★
DIRECTOR
Wasman Jane
Purchase · 50.0K shares
2026-01-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
Maxim Group BUY

SECTORS PEERS

PEERPRICE
OABI$4.47COMPARE
PRLD$5.47COMPARE
CCCC$3.85COMPARE
IVVD$0.96COMPARE
TARA$3.82COMPARE
CDXS$1.59COMPARE
MDWD$12.66COMPARE
NTHI$4.69COMPARE